Table 1.
Association between FAP protein expression and clinicopathological features in the TMA cohort.
| Clinical features | Frequency | Intensity | ||||
|---|---|---|---|---|---|---|
| High FAP expression | Low FAP expression | p | High FAP expression | Low FAP expression | p | |
| Age (years) | ||||||
| <59 | 9 (82%) | 2 (18%) | 0.64 | 7 (64%) | 4 (36%) | 0.11 |
| 60–69 | 16 (73%) | 6 (27%) | 11 (50%) | 11 (50%) | ||
| 70–79 | 24 (86%) | 4 (14%) | 23 (82%) | 5 (18%) | ||
| >80 | 23 (74%) | 8 (26%) | 19 (61%) | 12 (39%) | ||
| Sex | ||||||
| Male | 42 (78%) | 12 (22%) | 1 | 34 (63%) | 20 (37%) | 0.66 |
| Female | 30 (79%) | 8 (21%) | 26 (68%) | 12 (32%) | ||
| Tumor location | ||||||
| Cecum | 14 (82%) | 3 (18%) | 0.96 | 13 (76%) | 4 (24%) | 0.73 |
| Ascending colon | 12 (80%) | 3 (20%) | 8 (53%) | 7 (47%) | ||
| Transverse colon | 4 (80%) | 1 (20%) | 4 (80%) | 1 (20%) | ||
| Descending colon | 6 (67%) | 3 (33%) | 5 (56%) | 4 (44%) | ||
| Sigmoid colon | 20 (77%) | 6 (23%) | 16 (62%) | 10 (38%) | ||
| Rectum | 16 (80%) | 4 (20%) | 13 (65%) | 7 (35%) | ||
| Stage | ||||||
| I | 10 (59%) | 7 (41%) | 0.03 | 11 (65%) | 6 (35%) | 0.14 |
| II | 19 (70%) | 8 (30%) | 13 (48%) | 14 (52%) | ||
| III | 25 (93%) | 2 (7%) | 20 (74%) | 7 (26%) | ||
| IV | 18 (86%) | 3 (14%) | 16 (76%) | 5 (24%) | ||
| Grade | ||||||
| Low | 51 (75%) | 17 (25%) | 0.26 | 40 (59%) | 28 (41%) | <0.05 |
| High | 21 (88%) | 3 (12%) | 20 (83%) | 4 (17%) | ||
| Tumor: stroma* | ||||||
| Stroma low | 55 (77%) | 16 (23%) | 1 | 46 (65%) | 25 (35%) | 1 |
| Stroma high | 17 (68%) | 4 (32%) | 14 (66%) | 7 (34%) | ||
| Microsatellite instability* | ||||||
| MSI | 9 (90%) | 1 (10%) | 0.45 | 9 (90%) | 1 (10%) | 0.09 |
| MSS | 62 (77%) | 19 (23%) | 50 (62%) | 31 (38%) | ||
| Lymphatic invasion | ||||||
| Positive | 26 (90%) | 3 (10%) | 0.09 | 24 (83%) | 5 (17%) | <0.01** |
| Negative | 34 (71%) | 14 (29%) | 24 (50%) | 24 (50%) | ||
| Venous invasion* | ||||||
| Positive | 16 (76%) | 5 (24%) | 1 | 13 (61%) | 8 (38%) | 1 |
| Negative | 44 (76%) | 14 (24%) | 35 (60%) | 23 (40%) | ||
| Lymphovascular invasion* | ||||||
| Positive | 32 (84%) | 6 (16%) | 0.2 | 29 (76%) | 9 (24%) | 0.03 |
| Negative | 33 (72%) | 13 (28%) | 24 (52%) | 22 (48%) | ||
All 2 × 2 contingency tables were analyzed with Fisher exact tests. All others by χ2 test.
*
Patients with data not available, unknown, and discrepancies.
**
Statistical power estimated by bootstrapping.